ReviewInternational journal of molecular sciences2017
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma.Medicine · 2019Pooled it
- Article
- Sunitinib and TB lymphadenitis: An unexpected link in oncological therapy: a case report.Medicine · 2025Article
- An oncogenic role of lncRNA SNHG1 promotes ATG7 expression and autophagy involving tumor progression and sunitinib resistance of Renal Cell Carcinoma.Cell death discovery · 2024Article
- Discovery of A Novel Series of Quinazoline-Thiazole Hybrids as Potential Antiproliferative and Anti-Angiogenic Agents.Biomolecules · 2024Article
- Article
- Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.Frontiers in oncology · 2024Review
- Computer-assisted discovery of natural inhibitors for platelet-derived growth factor alpha as novel therapeutics for thyroid cancer.Frontiers in pharmacology · 2024Article
- Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation.Pharmaceutical biology · 2023Article
- Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect.Redox report : communications in free radical research · 2023Article
- Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.BMC complementary medicine and therapies · 2023Article
- Recurrent submandibular fistula after Sunitinib treatment in a patient with renal cell carcinoma: a case report.Medicine and pharmacy reports · 2023Article
- Glucosamine-Modified Reduction-Responsive Polymeric Micelles for Liver Cancer Therapy.Molecules (Basel, Switzerland) · 2023Article
- Imidazolylpyrrolone-Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma.ChemMedChem · 2023Article
- Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma.Frontiers in immunology · 2023Article
- Three-Dimensional Growth of Prostate Cancer Cells Exposed to Simulated Microgravity.Frontiers in cell and developmental biology · 2022Article
- Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.Investigational new drugs · 2021Article
- Imidazoles as Potential Anticancer Agents: An Update on Recent Studies.Molecules (Basel, Switzerland) · 2021Review
- Merkel Cell Carcinoma.Biomedicines · 2021Review
- Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.Diseases (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles. Phase III studies presented promising response rates and acceptable safety profiles of axitinib and tivozanib compared to sorafenib, and a phase II study reported greater efficacy using a combination of bevacizumab and IFN-α compared to sunitinib. Treatment with nintedanib exhibited a notably low prevalence of hypertension compared to sunitinib. The use of sorafenib and sunitinib are challenged by new drugs, but do not appear likely to be substituted in the near future. To clarify whether newer targeted drugs should replace sorafenib and sunitinib, more research is needed. This manuscript reviews the current utility and adverse effects of sorafenib and sunitinib and newer targeted therapies in the treatment of mRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.